126 related articles for article (PubMed ID: 32038880)
1. Response to anti-PD1 immunotherapy in patients with metastatic cutaneous sarcoma: case reports and literature review.
Vieira AC; Megid TBC; Melo R; Muniz D; Salgues ACR; Barbosa FG; Munhoz RR; Feher O
Oxf Med Case Reports; 2020 Jan; 2020(1):omz138. PubMed ID: 32038880
[TBL] [Abstract][Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous angiosarcoma: A review of current evidence for treatment with checkpoint inhibitors.
Guan L; Palmeri M; Groisberg R
Front Med (Lausanne); 2023; 10():1090168. PubMed ID: 36993810
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
6. Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma.
Soleymani T; Tyler Hollmig S
Curr Treat Options Oncol; 2017 Aug; 18(8):50. PubMed ID: 28762020
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas.
Helbig D; Klein S
Front Oncol; 2022; 12():975342. PubMed ID: 36465341
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors.
Klein S; Persa OD; Mauch C; Noh KW; Pappesch R; Wagener-Ryczek S; Buettner R; Quaas A; Helbig D
Oncoimmunology; 2019; 8(12):e1665977. PubMed ID: 31741767
[TBL] [Abstract][Full Text] [Related]
10. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
Heeke S; Hofman P
Transl Lung Cancer Res; 2018 Dec; 7(6):631-638. PubMed ID: 30505707
[TBL] [Abstract][Full Text] [Related]
11. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT; Shenasa E; Nielsen TO
Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
[TBL] [Abstract][Full Text] [Related]
12. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma.
Miller K; Goodlad JR; Brenn T
Am J Surg Pathol; 2012 Sep; 36(9):1317-26. PubMed ID: 22510760
[TBL] [Abstract][Full Text] [Related]
13. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
[TBL] [Abstract][Full Text] [Related]
14. Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response.
Guram K; Nunez M; Einck J; Mell LK; Cohen E; Sanders PD; Miyauchi S; Weihe E; Kurzrock R; Boles S; Sharabi AB
Front Oncol; 2018; 8():435. PubMed ID: 30386736
[No Abstract] [Full Text] [Related]
15. Sarcomas of the skin in the elderly.
Mentzel T
Clin Dermatol; 2011; 29(1):80-90. PubMed ID: 21146736
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
17. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
[TBL] [Abstract][Full Text] [Related]
18. Upper extremity pleomorphic dermal sarcoma in a patient with chronic myelomonocytic leukemia.
Capizzello A; Tatsiou Z; Prassopoulos P
Hippokratia; 2019; 23(4):181-185. PubMed ID: 32742171
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
Vargas AC; Maclean FM; Sioson L; Tran D; Bonar F; Mahar A; Cheah AL; Russell P; Grimison P; Richardson L; Gill AJ
PLoS One; 2020; 15(4):e0222551. PubMed ID: 32294103
[TBL] [Abstract][Full Text] [Related]
20. Pleomorphic Dermal Sarcoma of the Scalp.
Klebanov N; Hoang MP; Reddy BY
Cureus; 2018 Jul; 10(7):e2979. PubMed ID: 30237940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
